RxDoctor Payments Data

Mark Pinsky, DO

Family Medicine · Melbourne, FLNPI 1861485195

Payments from drug & device makers

$465in general payments, 2019–2025

Across 26 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$104
  • Abbott$97
  • Lilly USA, LLC$87
  • Novo Nordisk$38
  • Clarus Therapeutics Inc.$38
  • Novartis$25
  • plus $77 from 5 others

What the payments were for

  • Food & beverage$45498%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$465 in reported general payments places this provider in the 50th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$120,768
Medicare patients
184
Services billed
2,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$34,904
EliquisApixaban23$26,877
JardianceEmpagliflozin17$14,248
Spiriva HandihalerTiotropium Bromide12$5,905
SynthroidLevothyroxine Sodium52$5,293
Propafenone Hcl ErPropafenone Hcl11$4,093
Rosuvastatin Calcium212$3,873
Estradiol13$2,020
Levothyroxine Sodium123$1,858
Valsartan35$1,388
Insulin SyringeSyrge-Ndl,ins 0.3 Ml Half Mark13$1,364
Bupropion XlBupropion Hcl32$1,297
Testosterone Cypionate22$1,250
Nebivolol Hcl21$1,131
Levocetirizine Dihydrochloride36$1,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$38$34,90423 claims
AbbVieSynthroid$24$5,29352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →